Observational studyCancer control : journal of the Moffitt Cancer Center
Validation of the Taiwan Cancer Frailty Tool for Screening and Prognosis in Non-older Patients With Cancer: A Prospective Multicenter Study.
Observational study in Cancer control : journal of the Moffitt Cancer Center. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
IntroductionFrailty is a known predictor of poor outcomes in older patients with cancer; however, its recognition in non-older populations remains limited. In this prospective multicenter observational study, we compared the Taiwan Cancer Frailty Tool (TCFT) with the Flemish version of the Triage Risk Screening Tool (fTRST) and comprehensive geriatric assessment (CGA) in screening for frailty among non-older Taiwanese patients with cancer.MethodsWe prospectively enrolled 1,162 patients with cancer aged <65 years from multiple Taiwanese centers (2022-2024). Frailty was assessed using CGA (reference standard), TCFT, and fTRST, with frailty defined as ≥2 abnormal CGA domains. Both TCFT and fTRST were tested at two thresholds (>0 and >1). Diagnostic performance metrics and Kaplan-Meier survival analyses were performed.ResultsThe median patient age was 54 years (range, 20-64 years), and 74.6% were male. The predominant cancer types were head and neck, esophageal, and gastric/small bowel cancers. The prevalence of frailty was 44.0% (CGA), 65.0% (TCFT >0), and 73.4% (fTRST >0). TCFT >0 demonstrated a higher sensitivity (88.8%) and negative predictive value (86.0%) than fTRST >0 (88.5% and 80.9%, respectively). TCFT >1 provided superior specificity (93.1%) and positive predictive value (83.5%). The area under the curve for TCFT was significantly higher than that for fTRST (0.788 vs. 0.748; p = 0.012). All tools predicted poor survival, with TCFT exhibiting a more consistent prognostic performance across thresholds than fTRST.ConclusionFrailty is prevalent and prognostically significant in non-older patients with cancer. TCFT demonstrated superior diagnostic and prognostic utility compared with fTRST, supporting its integration into routine frailty screening for this population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.